Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
| 43.71 Delayed Data As of Nov 23 |  +0.10 / +0.23%Today’s Change | 38.40 Today|||52-Week Range 67.88 | -29.25% Year-to-Date |
Latest ENTA News | Press Releases
| Enanta Pharmaceuticals Inc (ENTA) Q4 2020 Earnings Call Transcript Nov 23 / MotleyFool.com - Paid Partner Content | Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for Nov 12 / Zacks.com - Paid Partner Content |
| Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates Nov 23 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 43.57 |
| Today’s open | 44.26 |
| Day’s range | 43.24 - 45.14 |
| Volume | 112,872 |
| Average volume (3 months) | 166,935 |
| Market cap | $875.3M |
Data as of 3:59pm ET, 11/23/2020
Growth & Valuation
| Earnings growth (last year) | -36.62% |
| Earnings growth (this year) | -158.76% |
| Earnings growth (next 5 years) | -83.30% |
| Revenue growth (last year) | -0.69% |
| P/E ratio | 437.1 |
| Price/Sales | 6.14 |
| Price/Book | 1.86 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AMPHAmphastar Pharmaceut... | -0.44 | -2.40% |
| CLLSCellectis SA | +0.96 | +4.54% |
| TCRRTCR2 Therapeutics In... | -0.81 | -2.98% |
| KRYSKrystal Biotech Inc | +2.00 | +4.74% |
Data as of 3:59pm ET, 11/23/2020
Financials
| Next reporting date | February 10, 2021 |
| EPS forecast (this quarter) | -$0.85 |
| Annual revenue (last year) | $205.2M |
| Annual profit (last year) | $46.4M |
| Net profit margin | 22.60% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Watertown, Massachusetts |
Forecasts
